Takeda Pharmaceutical (NYSE:TAK) Insider Sells $392,564.70 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Agosti Marcello Pignagnoli sold 22,957 shares of Takeda Pharmaceutical stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $17.10, for a total transaction of $392,564.70. Following the sale, the insider directly owned 176,977 shares in the company, valued at $3,026,306.70. This trade represents a 11.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Price Performance

NYSE:TAK traded down $0.06 on Wednesday, hitting $17.42. The company had a trading volume of 2,004,364 shares, compared to its average volume of 4,402,927. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $55.82 billion, a price-to-earnings ratio of 51.24 and a beta of -0.08. The firm has a 50 day moving average of $16.49 and a two-hundred day moving average of $17.13.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The firm had revenue of $6.90 billion for the quarter. On average, research analysts anticipate that Takeda Pharmaceutical Co. will post 3.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TAK shares. Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Wall Street Zen upgraded Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. Finally, Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Institutional Trading of Takeda Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in Takeda Pharmaceutical by 11.0% during the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock worth $6,558,000 after purchasing an additional 43,706 shares during the last quarter. AQR Capital Management LLC grew its position in shares of Takeda Pharmaceutical by 43.6% in the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after buying an additional 59,442 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Takeda Pharmaceutical by 15.0% in the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after buying an additional 692,404 shares during the period. Focus Partners Wealth raised its position in shares of Takeda Pharmaceutical by 4.1% during the first quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock worth $1,230,000 after acquiring an additional 3,239 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new position in shares of Takeda Pharmaceutical during the second quarter worth about $351,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.